Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial
Study limitation reported by the research below: “57% of participants had deficient or inadequate vitamin C levels at baseline, so results may reflect correction of deficiency rather than a pharmacological effect at replete levels.”